A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.

• DOI: 10.1200/jco.1989.7.4.477
• Publication Date: 2017-02-23T18:21:22Z
• Authors: J P Dutcher; S Creekmore; G R Weiss; K Margolin; A B Markowitz; M Roper; D Parkinson; N Ciobanu; R I Fisher; D H Boldt
• Keywords: Lymphocytosis; Regimen; Aldesleukin

Thirty-six patients with metastatic melanoma were entered into a study of the therapeutic efficacy adoptive immunotherapy high-dose interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells. Thirty-two who received all components therapy are evaluable for response, toxicity. Sites disease included lung, liver, subcutaneous nodules, intra-abdominal metastases. One complete response (CR) five partial responses (PRs) resulted from treatment (19% rate). The median duration was 5 months, durable CR continuing at 31+ months one PR 13 months. lymph nodes. Response, duration, or site did not correlate total dose IL-2 administered, rebound lymphocytosis, number LAK cells infused. Toxicity hypotension, fluid retention "capillary leak syndrome" in most patients, transient multiorgan dysfunction that resolved promptly after completion therapy. Adverse cardiac events occurred 16% myocardial infarction leading to death. This confirms activity initial IL-2/LAK cell regimen reported by Rosenberg et al, supporting concept as an important new approach this disease.